Replies to post #8885 on Inergetics Inc (fka NRTI)

[RobinIV]

Thanks. What i refer to is this: either MSE is important for NRTI, or it's not. If it is important for NRTI, it does not sound very "straight shooter with a solid financial background"-like to not be able to do the payments.

Also I do not agree that you can suggest in one post that NRTI is something for serious investors, and that they have to 'bet' on the chances of survival.

That's why I say that I do regret we're left in the dark about the strategy.

[crookedneck]

Excellent post and dead on! I said earlier that Martha Stewart does not want her MSE to fail and would do what it takes to make the MSE brand a success. I am sure she would be willing to work out a plausible plan regarding the royalty agreement. Mr. James is the best you will ever find in the OTC markets and all these new brands are still less than a year old and it takes time to successfully build a brand. Most importantly is your comment about NRTI not being involved some BS hype, that is not how they operate. We are seeing a transformation in progress and it doesn't happen overnight.

Their plans for the future are to grow their current brands through additional distribution and financially prudent promotional activity. They will also continue their masterful work plan to enter the medical MJ space that would give them a huge competitive edge in the marketplace.

The facts regarding NRTI are there for everyone to see and management is not participating in any games to fool anyone. This is work in progress and given what they accomplished to date, new management has given this company a real shot of becoming very successful long term, but it will be an uphill battle to get there. Mr. James understands this and is doing everything in his power to make that happen. He has made it clear many times that their plan is to increase distribution and use financially responsible promotional campaigns to increase brand awareness, to increase sales.

Mr. James has been very clear from the start that to turn this company around they would need increase sales to support the company. Thus he has and will continue to seek out new opportunities while continuing to build their current brands. This strategy is very straight forward and has not changed. Despite the challenges in the market, Mr. James feels confident that they will succeed in becoming cash flow positive in the longer term.

In his continued search for big opportunities, he worked out a deal to create a partnership with Terra Tech to enter the hottest growing sector for the next five years, medical marijuana supplements, to take advantage of a huge outage missing from this sector, which is to involve the top scientific researchers and medical physicians in the MJ sector in developing a whole new line of CBD supplements. It is true that this will take some time to develop, but the strategy behind it makes perfect sense and will position the company to increase sales very quickly, once the brand is created and in the market and have the support and endorsement from this advisory board Mr. James created. Now we all know this won't happen until next year, but the potential for the next 5 years is tremendous and could pay off huge for early investors.

This a speculative opportunity for those who can stomach the volatility of being in the OTC markets. This will surely require some additional financing and some dilution, which is to be expected at this early stage. What sets NRTI apart from so many in the OTC markets is the fact that any financing activity will be done responsibly to keep this as low as possible. Mr. James understands the negative affect that dilution can have on investors and tries to utilize as many other outside opportunities to avoid as much dilution as possible. This was easily seen during the past 2 years where he went out and secured over $5 million in government grants by moving the company offices across the river into a special development district. This helped to support and grow the company for the past 2 years and He will continue to seek out any opportunities to get the best possible financing terms as possible. However, you should all know that the financing terms for a small company trying to turn things around are less than desirable. Mr. James has an excellent track record and extensive experience in finance and he will use that expertise to get the best possible terms. If you compare the amount of dilution here to the vast majority of other companies in the OTC markets, you would see that the dilution here is much less and being handled in a responsible manner.

NRTI has a very reasonable shot IMHO, to turn things around and become very successful with their entry into the CBD supplement business. The other brands should also continue to grow behind their plan to expand distribution and responsible promotional spending. This is purely my opinion after reviewing the facts to date and urge everyone to do their own DD before making an investment decision. The road will be rough, but I believe we have the best management available to make it all happen without the hype and games running rampant in the OTC market. I also expect to see news worthy press releases on our current brands and on the CBD project on an ongoing basis. Cheers!

Disclosre: I am long w/828,500 shares.

For review, this is what the new management team here has accomplished in the past 2 years alone:

Since taking over 2 years ago, Mr. James and his leadership team have accomplished the following, which again, speaks volumes about how he operates and what he can accomplish:

* Reformulated the entire Surgex line. Along with enlisting upcoming athletes to endorse and help market the brand, such as Surgex Sports Nutrition Spokesperson Keenan Allen of the San Diego Chargers - Named NFL Offensive Rookie of the Year. Not to mention that Surgex is also the preferred sports nutrition brand for Army Sports.

* Launched an exclusive, high performance, private label protein shake for Muscle Maker Grill – one of the fastest growing health food franchises in the U.S. The private label shake which is currently shipping, carries the Muscle Maker Grill "42" moniker. It comes in three great tasting flavors – Vanilla, Chocolate and Strawberry - and will be available for sale at all 70 Muscle Maker Grill franchises on March 1st. Under the agreement, Inergetics will supply an estimated 600,000 shakes to Muscle Maker Grill franchises over the next 12 months. Inergetics also worked in partnership with Muscle Maker Grill to develop a custom product design, as well as an online ordering system for its franchisees.

* Created the Martha Stewart Essentials line and brokered a deal with Martha Stewart to bring it all together. Then sold the entire line into Walgreen's that forced distribution to all their stores across the US to kick things off. Not to mention the distribution across other chains and numerous online vendors, with much more in the works, such as Cardinal Health, announced today.

* Bought the Bikini Ready & Slim Trim brands and developed a National marketing plan with well known women surfer's to help endorse and market the brand across the US. As well as getting new distribution at retail chains and online stores. The Bikini Ready brand is quickly gaining popularity through social media and off to great start, with Slim Trim trailing along as an economical alternative.

* Relocated the company to the Innovation Zone of Newark, NJ to receive cash after fees of over $5 million net to date from the New Jersey Technology Business Tax Certificate Transfer Program. This state funding was non-dilutive and did not add shares or debt to the capital structure of the company. This funding was reinvested into the business to help expand its product offerings and achieve greater distribution of its existing product lines.

* Acquired the Intrinsix brand and developed a distribution agreement with Podiatree to sell the brand at their locations across the US without the need to spend any promotional dollars.

* Acquired OmEssentials, a private company dedicated to the development of advanced nutritional formulations and progressive nutrition education supporting the yoga, wellness and health food industries. The strategic purchase allows for expansion into new markets and continued diversification of their nutritional supplements.

* Entered into Strategic Partnership with Terra Tech Corporation to Develop a New Line of Hemp Oil-Based Nutritional Supplements.

* Created their own Scientific/Medical Advisory Board to help guide in the formulation of the proprietary line of natural Cannabidiol (CBD)-based nutritional supplements. They were able to recruit some of the best minds in the medical marijuana industry that have studied and worked in the field for a very long time and well admired by their peers. The ability to assemble such an all star cast with such extensive credentials to help create and endorse these supplements is something NONE of the other MJ companies have even attempted, making this approach very exclusive and give this partnership a huge competitive advantage that will be unmatched in the MJ supplement market. They are:

Dr. Yu Shao, who has extensive experience in product research and development across many areas of health and wellness, specializing in pharmaceutical extraction methods and plant biochemistry – as well as formulating herbal and botanical nutritional products. He brings almost two decades of expertise in these fields working with a variety of global firms, including Glaxo Smith Kline, Wyeth (now Pfizer), and Merck, directing the launch of more than 30 innovative new products for these companies.

Dr. Joseph McSherry who is a Neurologist who has extensive knowledge of research involving the medical benefits of cannabis and its cannabinoids for pain management, medicinal and therapeutic use. He is a widely recognized academic expert on medical cannabis/cannabinoids and its many health benefits, and is also involved in several community service initiatives including his service on the State of Vermont's Marijuana Oversight Committee. Dr. McSherry is the author of numerous academic and public presentations on the medical use of cannabis/cannabinoids in general and as it relates to cancer and other specific medical conditions. He received theOutstanding Physician Advocate Award from the Washington, D.C.-based Marijuana Policy Project in 2010.

Dr. Michelle Sexton who is a highly-respected expert in the medicinal applications of cannabis, naturopathic medicine and the phytochemistry of plant medicine, with more than 15 years of experience in natural, herbal and holistic medicine. She currently serves as the Executive Medical Research Director at the Center for the Study of Cannabis and Social Policy in Seattle. For the past several years, she owned and operated Phytalytics LLC, doing business as PhytaLab, a phytochemical analysis company dedicated to developing and perfecting analytical platforms for the quality control of medical and adult use cannabis and related products in Washington state.

Dr. Mark Wallace is an acclaimed anesthesiologist specializing in pain management, with deep experience researching innovative pain treatments and performing in-depth clinical trials on all types of pain. He is board certified in both anesthesiology and pain medicine in the State of California, and is on faculty at the University of California San Diego Health System and the Veterans Affairs San Diego Healthcare System. At UC San Diego, Dr. Wallace serves as the chair of the Division of Pain Medicine and is a Professor of Clinical Anesthesiology. He is also the Director, Division of Clinical Research, UCSD Clinical and Translational Research Institute. He is actively involved in all aspects of clinical care, graduate medical education/training and research. Dr. Wallace's research on pain medicine has been widely published in an extensive array of peer-reviewed medical journals and books. He is also the recipient of numerous grants, including grants from Pfizer, Medtronic and Abbott Laboratories.

Dr. Fischedick is a respected expert in the therapeutic and medicinal properties of chemical components of plants, specifically Cannabis. He brings years of experience in advanced chromatography and spectrometry, including proven abilities in the isolation of natural products for scientific and medical analysis. Dr. Justin Fischedick is currently a Postdoctoral Research Associate at the Institute of Biological Chemistry at Washington State University, and has authored or co-authored several scientific articles on Cannabis, cannabinoids and terpenoids published in top scientific and medical journals. He has presented his scientific research at a number of national and international conferences including the Phytochemical Society of North America conference, the International Conference on Natural Products Research and the International Association for Cannabinoids as Medicine (IACM) conference.


* On June 4th they held their Inaugural Meeting of its Scientific/Medical Advisory Board to share expertise and insights on the benefits of CBD-based medicinal products, and develops product development plan. The advisory board is responsible for guiding the formulation of the proprietary line of natural Cannabidiol (CBD)-based nutritional supplements the company is developing in partnership with Terra Tech Corp. (TRTC).

Here are the results and comments from that inaugural meeting that everyone NEEDS to review, because it will give you a clear direction of where this company is headed in the medical MJ industry, spoken from these experts on this advisory board:

Together with Inergetics' CEO Mike James, CMO Jim Kras and Chief Science Officer, Carl Germano, RD, CNS, CDN, the group discussed the numerous health benefits of CBD and how they may best be delivered to patients. The meeting also produced a consensus on the next steps toward the development of CBD-based products.

"We are making clear progress in the development of superior CBD-based products that will offer a natural and workable remedy to patients seeking relief from a range of symptoms," said Carl Germano. "Certain cannabinoids are non-psychoactive, and proven to provide safe and effective relief to those suffering from pain, nausea, neurological disorders and other ailments. I could not have been more pleased with the substance of our discussion, and the plan we have devised for bringing our first CBD product to market."

Advisory Board member Dr. Joseph McSherry, M.D., a Neurologist and widely recognized academic expert on medical marijuana and its many health benefits, said, "An effort such as this is unprecedented. We have come so far since I first started advocating for the medicinal applications of Cannabis, and I am excited about working with this impressive group of colleagues to bring the therapeutic properties of CBD-based supplements to the consumers who could most benefit from them."

"Cannabinoids undoubtedly provide relief from pain and its underlying symptoms, and do so with far fewer side effects than other treatments currently available," said Dr. Mark Wallace, M.D., a member of the Advisory Board and the Chair of the Division of Pain Medicine at University of California San Diego. "CBD is a clear and essential alternative remedy for patients, and I think we are all eager to make this resource available to the public, and at a higher-quality."

Advisory Board member Dr. Michelle Sexton, a certified naturopathic doctor, said, "I look forward to working with this impressive group to take the first critical look at the proper dosage, potency, purity and methods of administration of cannabinoids. Right now there is no clear industry standard, and this team has an opportunity to change that."

"Twenty-five percent of drugs in the market today come from natural sources. Cannabis is just another one of those natural sources that can be used to help patients," said Justin Fischedick, PhD, a member of the Advisory Board and an expert in plant chemistry.

Dr. Yu Shao, Advisory Board member and also a consultant for Merck, added, "Inergetics and Terra Tech can help define the future of medicinal Cannabis, and I am pleased to be a part of this effort."

The strategic partnership between Inergetics and Terra Tech Corp was announced on February 4 and the companies' first CBD-based supplements are expected to be distributed via medicinal marijuana dispensaries. Inergetics announced the formation of the Scientific/Medical Advisory Board on March 5.


Continuing updates on the work of the Advisory Board and on the CBD product initiative will be available at www.inergetics.com/cbd-initiative/.